PFS was based on RECICL (Response Evaluation Criteria in Cancer of the Liver) in the intention-to-treat (ITT) population. The 6-month PFS was 70.8% with TACE-CR and 31.5% with TACE alone.

To date, there is no evidence that TACE pre-liver transplantation or resection helps to expand current selection criteria for patients with HCC, nor results in less recurrence after surgery.

To date, there is no evidence that TACE either before resection or liver transplantation helps to expand current selection criteria for patients with HCC or prevent recurrence.

The combination of transarterial chemoembolization (TACE) with camrelizumab and rivoceranib (apatinib) significantly improved progression-free survival (PFS) in patients with unresectable ...

Or they might also give a chemotherapy drug to the liver at the same time. This is called trans arterial chemoembolisation (TACE). TAE can help to reduce the size of the NET in the liver. It can also ...

This study is to evaluate the effect of adjuvant transarterial chemoembolization (TACE) for Barcelona Clinic Liver Cancer (BCLC) stage A HCC patients after hepatectomy. Methods: Consecutive HCC ...

For BCLC stage B patients with good liver function, transarterial chemoembolization (TACE) is the first-choice treatment method. However, some patients may not benefit from TACE, so systemic therapy ...

A 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in ...

Promising Liver Cancer Therapies such as Atezolizumab, Bevacizumab, Tiragolumab, OH2 injection, MTL-CEBPA, Sorafenib 200mg, ...